OptiBiotix Health of York, which develops products to tackle obesity, high cholesterol, diabetes and skincare, has increased its partners in its key markets of Asia and the US.
It has also invested in e-commerce channels nationally, and subsequently internationally to deliver direct-to-consumer sales, reducing reliance on retail partners.
Sales momentum is also building, above 2023 levels.
RECOMMENDED READING:
Stephen O’Hara, CEO, said: “Having spent a number of years carrying out clinical studies to gain health claims on our first generation products, we are now gaining commercial traction with large partners in key markets.
“We anticipate this trend will continue in 2024 and hope to add to this other partners who are interested in our potentially industry changing second-generation products.
“With appetite suppression, gut health, sugar alternatives, and modulation of the human microbiome attracting ever-increasing interest, we look to the future with a high degree of confidence.”
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here